Hjem
Kimberley Joanne Hatfields bilde

Kimberley Joanne Hatfield

Gjesteforsker, Leukemia Research Group
  • E-postkimberley.hatfield@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

Prosjektet undersøker effekten av ulike medikamenter som blokkerer sentrale metabolske signalveier i akutt myeloid leukemi (AML). Prosjektet har som mål å karakterisere ulike metabolske signalveier i leukemiceller, samt autofagi, og studere hvordan dette bidrar til kjemoresistens i AML. Prosjektet er støttet av midler fra Bergens forskningsstiftelse.

  • Vis forfatter(e) (2022). Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients. Cancers. 21 sider.
  • Vis forfatter(e) (2022). NPM1-mutated patient-derived AML cells are more vulnerable to rac1 inhibition. Biomedicines. 16 sider.
  • Vis forfatter(e) (2022). MicroRNA serum profiles and chronic graft-versus-host disease. Blood Advances. 5295-5306.
  • Vis forfatter(e) (2022). Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules.
  • Vis forfatter(e) (2021). Effects of the autophagy‐inhibiting agent chloroquine on acute myeloid leukemia cells; characterization of patient heterogeneity. Journal of Personalized Medicine. 1-23.
  • Vis forfatter(e) (2020). The PI3K-AKT-MTOR signaling pathway in human acute myeloid leukemia (AML) cells. International Journal of Molecular Sciences. 1-22.
  • Vis forfatter(e) (2020). Targeting cellular metabolism in acute myeloid leukemia and the role of patient heterogeneity. Cells. 1-26.
  • Vis forfatter(e) (2019). Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells.
  • Vis forfatter(e) (2019). Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy.
  • Vis forfatter(e) (2018). Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.

Se fullstendig oversikt over publikasjoner i CRIStin.

2016-2020: Metabolic phenotypes of leukemia cells.